Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 49, Issue 11, Pages 1813-1818Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.107.050237
Keywords
endocrinology; hyperparathyroidism; sestamibi; endoscopic exploration; minimally invasive single-gland exploration; parathyroid hormone assays
Funding
- NCI NIH HHS [T32 CA009685] Funding Source: Medline
Ask authors/readers for more resources
Primary hyperparathyroidism is the most common cause of hypercalcemia, and the treatment is primarily surgical. Because of biochemical screening, more patients now present with asymptomatic primary hyperparathyroidism, and consensus guidelines have been developed for the treatment of these patients. There is now considerable interest in minimally invasive approaches to the treatment of hyperparathyroidism. Sestamibi scanning as a localizing study, used in combination with anatomic imaging and intraoperative rapid parathyroid hormone assays, has enabled focused surgical approaches. Patients with localizing studies that indicate a single parathyroid adenoma are candidates for such approaches, including unilateral neck exploration, minimally invasive single-gland exploration, or endoscopic exploration instead of the traditional approach of bilateral neck exploration. Nuclear imaging is also critical to the successful management of patients with persistent or recurrent hyperparathyroidism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available